EUVIMEDEUVIMED entdecken
Crossref

Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer

Wen Ding, Jianshan Mo, Yingxue Su, Qiyi Zhang, Danyuan Sun, Xiangchao Yao, Guopin Liu, Jiangling Ye, Yanle Wu, Menghan Xue, Peibin Yue, Jinjian Lu und 6 weitere

Drug Resistance Updates · 2025-09 · 82 · 101272

DOI: 10.1016/j.drup.2025.101272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-09. Verfasst von Wen Ding und 17 weiteren Autor:innen. Beteiligte Einrichtung: National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Tumor-Associated Macrophages, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Guangdong Provincial Natural Science Foundation, Department of Science and Technology of Jilin Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunosuppression within the tumor microenvironment (TME) is frequently associated with chemoresistance. However, the mechanisms by which chemoresistance promotes immune evasion and impairs subsequent immunotherapy remain poorly understood, underscoring the urgent need for novel therapeutic strategies to counteract these effects. In this study, we observed that tumors exhibit cross-resistance to immunotherapy following chemoresistance in a non-small cell lung cancer (NSCLC) mouse model. The aberrant accumulation of tumor-associated macrophages (TAMs) and extracellular adenosine (Ado) were identified as mediators of immunosuppression, fostering cross-resistance to immunotherapy in the context of chemoresistance. Mechanistically, selective activation of the Ado/A2AR signaling pathway induced metabolic reprogramming of TAMs, thereby creating an immunosuppressive niche in cross-resistant NSCLC. Based on these findings, we designed a novel selective A2AR inhibitor DL082 and explored its therapeutic potential for treating cross-resistant NSCLC. The combination of DL082 with an anti-PD-L1 antibody significantly enhanced immune activation and inhibited tumor progression in cross-resistant NSCLC. These findings elucidate the specific mechanisms underlying cross-resistance between chemotherapy and immunotherapy in NSCLC and propose targeting the Ado-TAM axis as a potential strategy for overcoming resistance in NSCLC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmTumor-Associated MacrophagesLung NeoplasmsReceptor, Adenosine A2AAnimalsMiceTumor MicroenvironmentHumansSignal TransductionAdenosineCell Line, TumorAdenosine A2 Receptor AntagonistsB7-H1 AntigenImmunotherapyImmune Checkpoint InhibitorsMetabolic Reprogramming

Stichwörter der Autor:innen

AdenosineCross-resistanceImmunotherapyNSCLCTAM

Substanzen

AdenosineReceptor, Adenosine A2AAdenosine A2 Receptor AntagonistsB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 5…
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
  • Department of Medicine, Division of Hematology-Oncology, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 999074, Macao Special Administrative Region of China.
  • Department of Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Innovation Practice Center, Changchun University of Chinese Medicine, Changchun 130117, China.

Förderung

  • Guangdong Provincial Natural Science Foundation
  • Department of Science and Technology of Jilin Province
  • National Natural Science Foundation of China
  • Key Technologies Research and Development Program of Guangzhou Municipality
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia
  • Guangdong Provincial Key Laboratory of Construction Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Traditional Chinese Medicine Bureau of Guangdong Province

Zitieren

APA

Ding, W., Mo, J., Su, Y., Zhang, Q., Sun, D., Yao, X., Liu, G., Ye, J., Wu, Y., Xue, M., Yue, P., Lu, J., Zhang, J., Shi, Y., Hu, W., Zhu, K., Wang, Y., & Zhang, X. (2025). Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer. Drug Resistance Updates, 82, 101272. https://doi.org/10.1016/j.drup.2025.101272

Vancouver

Ding W, Mo J, Su Y, Zhang Q, Sun D, Yao X, et al. Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer. Drug Resistance Updates. 2025;82:101272. doi:10.1016/j.drup.2025.101272

BibTeX
@article{Ding2025,
  author = {Ding, Wen and Mo, Jianshan and Su, Yingxue and Zhang, Qiyi and Sun, Danyuan and Yao, Xiangchao and Liu, Guopin and Ye, Jiangling and Wu, Yanle and Xue, Menghan and Yue, Peibin and Lu, Jinjian and Zhang, Jian and Shi, Yanyu and Hu, Wenhao and Zhu, Kai and Wang, Yandong and Zhang, Xiaolei},
  title = {Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {82},
  pages = {101272},
  doi = {10.1016/j.drup.2025.101272}
}
Kostenlos starten →